Prinses Maxima Centrum voor Kinderoncologie B.V.
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment – Diagnosis
The centre leverages cutting‑edge imaging and molecular diagnostics to sharpen the detection and monitoring of paediatric cancers such as neuroblastoma and lymphomas, enabling more precise treatment decisions.
- Evaluation of [18F]mFBG PET‑CT versus [123I]mIBG SPECT‑CT for skeletal lesion detection
- Development of companion diagnostics for genetically modified T‑cell therapies
- Biomarker profiling to predict response to checkpoint inhibitors
These efforts aim to improve early diagnosis, guide therapy selection, and track disease dynamics for children treated at the Prinses Maxima Centrum.
Hemic and Lymphatic Diseases
Research in this area concentrates on blood‑forming and lymphatic malignancies—including acute lymphoblastic leukemia, acute myeloid leukemia, and various lymphomas—to test innovative targeted agents and cellular therapies.
- Phase I safety study of dasatinib + venetoclax in relapsed leukemia with MAPK/SRC mutations
- Inotuzumab ozogamicin for CD22‑positive B‑cell ALL
- Relatlimab + nivolumab in refractory Hodgkin lymphoma and NHL
- Quizartinib in FLT3‑ITD positive AML
The goal is to raise cure rates while reducing treatment‑related toxicity for young patients.
Immune System Diseases
This therapeutic focus explores immunotherapy strategies, including genetically modified T‑cell products, checkpoint blockade, and pathway‑specific inhibitors, to combat paediatric haematological cancers.
- Long‑term follow‑up of gene‑modified T‑cell recipients
- Pembrolizumab monotherapy safety and activity in solid tumours and Hodgkin lymphoma
- Ruxolitinib + venetoclax targeting IL‑7R/JAK‑STAT signalling
- Trametinib‑based combination for relapsed haematologic malignancies
By harnessing the immune system, the centre seeks durable remissions and improved survival for children with refractory disease.
Neoplasms
Broad investigations address solid tumours such as neuroblastoma, atypical teratoid/rhabdoid tumour, melanoma, and high‑risk lymphomas, evaluating radiopharmaceuticals, targeted drugs, and novel regimens.
- 177Lu‑DOTATATE therapy for high‑risk neuroblastoma
- High‑dose chemotherapy versus radiotherapy consolidation in ATRT infants
- Pembrolizumab combined with chemotherapy for early responders
- Vinblastine monotherapy for standard‑risk ALK‑positive ALCL
These studies aim to boost event‑free survival and achieve curative outcomes for children with aggressive solid tumours.
Nervous System Diseases
Dedicated efforts target central nervous system malignancies, particularly ATRT and neuroblastoma with bone involvement, integrating advanced imaging and intensified chemotherapy protocols.
- mFBG PET‑CT for skeletal lesion detection in neuroblastoma
- High‑dose chemotherapy consolidation for ATRT under 12 months
- MRD‑negativity assessment in FLT3‑ITD AML with CNS risk
- Safety monitoring of GM T‑cell therapy in paediatric patients
The aim is to enhance neurological outcomes and long‑term quality of life for young patients facing CNS‑related cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 176 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 169 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 28 by active trials.
lock +27 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Prinses Maxima Centrum voor Kinderoncologie B.V.
lock Showing 1 of 94 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20290) A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors | Bayer AG, Bayer Consumer Care AG | Phase I | Not Recruiting | Apr 2017 | Jun 2026 |
IMP list
lock Showing 1 of 176 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 18 | Unknown | 2014-03-27 | 2025-09-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.